Structure Therapeutics (GPCR) Total Non-Current Liabilities (2022 - 2026)

Structure Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $60.2 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 44.62% year-over-year to $60.2 million in Q1 2026; TTM through Mar 2026 was $60.2 million, a 44.62% increase from a year earlier, with the FY2025 full-year figure at $66.9 million, up 75.18% from the prior year.
• Total Non-Current Liabilities retreated to $60.2 million in Q1 2026 per GPCR's latest filing, from $66.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $66.9 million in Q4 2025 and bottomed at $13.0 million in Q4 2022.
• The 5-year median for Total Non-Current Liabilities is $37.1 million (2024), against an average of $38.9 million.
• Across the five-year window, Total Non-Current Liabilities jumped 121.01% in 2023 and surged 32.8% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $13.0 million in 2022, then soared by 121.01% to $28.8 million in 2023, then surged by 32.8% to $38.2 million in 2024, then jumped by 75.18% to $66.9 million in 2025, then decreased by 10.06% to $60.2 million in 2026.
• Per Business Quant, the three latest GPCR Total Non-Current Liabilities figures stand at $60.2 million (Q1 2026), $66.9 million (Q4 2025), and $61.8 million (Q3 2025).